Valence Discovery

High-Level Overview

Valence Discovery is an AI-driven drug discovery company that builds a machine learning platform for molecular design and optimization, enabling drug discovery teams to leverage deep learning for faster, cheaper, and more innovative therapeutic development.[1][2][3][4] Formerly known as InVivo AI, it serves pharmaceutical companies, contract research organizations like Charles River Labs, and academic labs by addressing challenges in sparse biomedical datasets to design high-quality drug candidates optimized for potency, selectivity, safety, and DMPK parameters.[3][4] The platform democratizes AI access, powering growth through partnerships like Servier and infrastructure on Google Cloud, which has reduced costs and accelerated R&D.[3][4]

Origin Story

Valence Discovery originated as a PhD biotech project at Mila, the world's largest deep learning research institute in Montreal, where the founding team developed deep learning tools for drug discovery during their studies.[2][3][4] Founded in 2018 by CEO and Co-Founder Daniel Cohen, the company rebranded from InVivo AI and is now a Recursion company, evolving from academic research to a commercial platform.[1][4] Early traction came from building AI tools adapted for incomplete biomedical data, leading to scalable deployment on Google Cloud and partnerships that shifted focus to empowering diverse R&D organizations.[3]

Core Differentiators

• AI Platform for Sparse Data: Uses deep learning techniques tailored for incomplete biomedical datasets, enabling rapid design of novel therapeutics in intractable biological areas.[3][4]
• Intuitive Infrastructure: Unifies best-in-class deep learning with user-friendly tools, allowing any drug team to become AI-enabled without heavy expertise.[1][2]
• Tech Stack Efficiency: Built on Google Cloud (GKE, Cloud Storage, Cloud Run) for scalable ML model training, simulations, and backend servers, cutting costs and speeding launches.[3]
• Proven Partnerships: Collaborates with entities like Servier for multi-target drug candidates and Charles River Labs, unlocking new chemical spaces.[3][4]
• Research Leadership: Pushes ML boundaries in drug design, now integrated with Recursion's platform for predicting and explaining biology.[5]

Role in the Broader Tech Landscape

Valence rides the wave of AI democratization in drug discovery, where deep learning tackles historically undruggable targets amid rising computational power and data generation advances.[3][4][5] Timing aligns with industry shifts toward AI-optimized candidates, with CEO Daniel Cohen predicting that by 2030, most clinical drugs will involve AI input, fueled by market forces like high R&D costs and the need for novel therapies.[4] It influences the ecosystem by partnering across scales—from academics to big pharma like Servier—accelerating access to advanced tools and fostering virtual cell models for simulating patient responses.[3][4][5]

Quick Take & Future Outlook

Valence is poised to expand as a Recursion-powered engine, advancing virtual cells and models like TxPert for out-of-distribution predictions in biology.[5] Trends in agentic AI systems, quantum mechanics datasets, and scalable cloud compute will shape its path, potentially dominating AI-driven small molecule design.[5][6] Its influence may evolve from tool provider to ecosystem leader, enabling broader shifts to AI-native drug pipelines and unlocking unprecedented therapeutic spaces—reinforcing its mission to empower every drug team from day one.[1][4]